ArticleThe Journal of clinical investigation2007
Lymphocytes genetically modified to express tumor antigens target DCs in vivo and induce antitumor immunity.
Article in The Journal of clinical investigation, 2007. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 25 citations in OpenAlex.
- Multi-engineered T cell vaccine boosting TCR-T cell therapy enhances anti-tumor function and eradicates heterogeneous solid tumors.Molecular therapy : the journal of the American Society of Gene Therapy · 2025Article
- A therapeutic cancer vaccine delivers antigens and adjuvants to lymphoid tissues using genetically modified T cells.The Journal of clinical investigation · 2021Article
- Dendritic Cells in Anticancer Vaccination: Rationale for Ex Vivo Loading or In Vivo Targeting.Cancers · 2020Review
- Antigen-loaded monocyte administration induces potent therapeutic antitumor T cell responses.The Journal of clinical investigation · 2020Article
- Therapeutic Regeneration of Lymphatic and Immune Cell Functions upon Lympho-organoid Transplantation.Stem cell reports · 2019Article
- Novel Targeting to XCR1Frontiers in immunology · 2019Article
- Transposon-modified antigen-specific T lymphocytes for sustained therapeutic protein delivery in vivo.Nature communications · 2018Article
- The administration of drugs inhibiting cholesterol/oxysterol synthesis is safe and increases the efficacy of immunotherapeutic regimens in tumor-bearing mice.Cancer immunology, immunotherapy : CII · 2016Article
- Improved anti-leukemia activities of adoptively transferred T cells expressing bispecific T-cell engager in mice.Blood cancer journal · 2016Article
- Whole blood cells loaded with messenger RNA as an anti-tumor vaccine.Advanced healthcare materials · 2014Article
- Identification of MAGE-C1 (CT-7) epitopes for T-cell therapy of multiple myeloma.Cancer immunology, immunotherapy : CII · 2011Article
- Immunization route dictates cross-priming efficiency and impacts the optimal timing of adjuvant delivery.Frontiers in immunology · 2011Article
- T cells as vehicles for cancer vaccination.Journal of biomedicine & biotechnology · 2011Review
- A Clinical Study of a Cell-Based MAGE-A3 Active Immunotherapy in Advanced Melanoma Patients.Journal of Cancer · 2011Article
- Induction of protective cytotoxic T-cell responses by a B-cell-based cellular vaccine requires stable expression of antigen.Gene therapy · 2009Article
- Artificial antigen-presenting cells for use in adoptive immunotherapy.Cancer journal (Sudbury, Mass.)Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors at 5 institutions in 3 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The exploitation of the physiologic processing and presenting machinery of DCs by in vivo loading of tumor-associated antigens may improve the immunogenic potential and clinical efficacy of DC-based cancer vaccines. Here we show that lymphocytes genetically modified to express self/tumor antigens, acting as antigen carriers, efficiently target DCs in vivo in tumor-bearing mice. The infusion of tyrosinase-related protein 2-transduced (TRP-2-transduced) lymphocytes induced the establishment of protective immunity and long-term memory in tumor-bearing mice. Analysis of the mechanism responsible for the induction of such an immune response allowed us to demonstrate that cross-presentation of the antigen mediated by the CD11c(+)CD8alpha(+) DC subset had occurred. Furthermore, we demonstrated in vivo and in vitro that DCs had undergone activation upon phagocytosis of genetically modified lymphocytes, a process mediated by a cell-to-cell contact mechanism independent of CD40 triggering. Targeting and activation of secondary lymphoid organ-resident DCs endowed antigen-specific T cells with full effector functions, which ultimately increased tumor growth control and animal survival in a therapeutic tumor setting. We conclude that the use of transduced lymphocytes represents an efficient method for the in vivo loading of tumor-associated antigens on DCs.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.